PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1 (vol 20, pg 917, 2017)

被引：5

作者：

Chen, Gang

Kim, Yong Ho

Li, Hui

Luo, Hao

Liu, Da-Lu

Zhang, Zhi-Jun

Lay, Mark

Chang, Wonseok

Zhang, Yu-Qiu

Ji, Ru-Rong

机构：

[1] Duke University Medical Center,Department of Anesthesiology

[2] Nantong University,Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co

[3] Gachon University,Innovation Center of Neuroregeneration

[4] Fudan University,Department of Physiology, College of Medicine

[5] Duke University Medical Center,Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science

来源：

NATURE NEUROSCIENCE | 2019年 / 22卷 / 03期

关键词：

D O I：

10.1038/s41593-018-0323-x

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

In the version of this article initially published, what was originally described as ‘conditioned place preference’ in a two-chamber mouse experiment could be better described as ‘conditioned place avoidance’.

引用

页码：503 / 503

页数：1

共 50 条

[31] Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
Wang, Suli
Nie, Fujiao
Yin, Qiuyue
Tian, Haoyang
Gong, Pizhang
Ju, Jinhong
Liu, Jiayi
Yang, Pishan
Yang, Chengzhe
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
[32] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee
Ju Yeon Lee
Heejin Lim
Sang Hyung Lee
Yu Jeong Moon
Hyo Jeong Pyo
Seong Eon Ryu
Woori Shin
Yong-Seok Heo
Scientific Reports, 7
[33] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Lee, Hyun Tae
Lee, Ju Yeon
Lim, Heejin
Lee, Sang Hyung
Moon, Yu Jeong
Pyo, Hyo Jeong
Ryu, Seong Eon
Shin, Woori
Heo, Yong-Seok
SCIENTIFIC REPORTS, 2017, 7
[34] Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, Xingcheng
Ma, Ling
Zhang, Xiaoying
Huang, Liang
Wei, Jia
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
[35] Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Xingcheng Yang
Ling Ma
Xiaoying Zhang
Liang Huang
Jia Wei
Experimental Hematology & Oncology, 11
[36] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li
Mengke Niu
Jianwei Zhou
Kongming Wu
Ming Yi
Cell Communication and Signaling, 22
[37] The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li, Tianye
Niu, Mengke
Zhou, Jianwei
Wu, Kongming
Yi, Ming
CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
[38] Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
Xiao, Xiyun
Zeng, Saitian
Li, Yanying
Li, Lingling
Zhang, Jiyan
JOURNAL OF ONCOLOGY, 2022, 2022
[39] Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction
Zhang, Feng
Yu, Qimeng
Wu, Caiyun
Sun, Shishi
Wang, Yu
Wang, Rui
Chen, Zejie
Zhang, Hua
Xiong, Xuqiong
Awadasseid, Annoor
Rao, Guowu
Zhao, Xiaoyin
Zhang, Wen
BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111
[40] Strong single-agent and PD-1/PD-L1 combination antitumor activity of antisense oligonucleotides suppressing Neuropilin 1 expression.
Petropoulos, Konstantin
Maaske, Andre
Kirchhammer, Nicole
Festag, Julia
Buchi, Melanie
Michel, Sven
Zippelius, Alfred
Klar, Richard
Jaschinski, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →